<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516618</url>
  </required_header>
  <id_info>
    <org_study_id>R475-PN-1516</org_study_id>
    <nct_id>NCT02516618</nct_id>
  </id_info>
  <brief_title>Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Fasinumab in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and tolerability of a single dose
      of subcutaneous (SC) or intravenous (IV) administered fasinumab in healthy Japanese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with fasinumab or placebo.</measure>
    <time_frame>Baseline to week 16 (End of Study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasinumab serum concentrations over time</measure>
    <time_frame>Baseline to week 16 (End of Study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-fasinumab antibodies over time</measure>
    <time_frame>Baseline to week 16 (End of Study)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 1 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 2 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 3 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 4 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 5 of Fasinumab or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fasinumab</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>REGN475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Healthy male or female Japanese and Caucasian volunteers ≥20 and ≤55 years of age at
             the screening visit

          2. Japanese subjects must:

               -  Be first generation Japanese, defined as born in Japan and having 4 biologic
                  grandparents who are ethnic Japanese

               -  Have maintained a Japanese lifestyle since leaving Japan

          3. Caucasian subjects must be Caucasian of European or Latin American descent

          4. Have a Body Mass Index (BMI) ≤ 35

          5. Be willing to refrain from taking NSAID medications (oral or topical) for 1 week prior
             to receiving study drug and for 16 weeks after study drug administration

        Key Exclusion Criteria:

          1. History or presence at the screening visit of bone or joint disorders including but
             not limited to osteoarthritis, avascular necrosis, destructive arthropathy, pathologic
             fractures, osteonecrosis, rheumatoid arthritis, neuropathic joint arthropathy, lupus
             erythematosus, or inflammatory joint diseases

          2. History of joint-related events such as, but not limited to, total joint replacement
             (TJR) surgery, patella dislocation, hip dislocation, knee dislocation, injury to
             meniscus or knee ligaments (with or without surgical repair), or joint infections

          3. Trauma to any joint in the 30 days prior to the screening visit

          4. History of autonomic neuropathy, or diabetic neuropathy

          5. Evidence of autonomic neuropathy

          6. Presence of clinically relevant peripheral neuropathy

          7. History or presence at the screening visit of orthostatic hypotension

          8. History or evidence at screening of heart block

          9. Resting heart rate of &lt;50 or &gt;100 beats per minute (bpm)

         10. History of poorly controlled hypertension:

         11. Congestive heart failure with NY Heart Classification of stage 3 or 4

         12. History of myocardial infarction, acute coronary syndromes, or cerebrovascular
             accident within 12 months prior to the screening visit

         13. Significant concomitant illness such as, but not limited to, cardiac, renal,
             neurological, endocrinological, GI, hepatic, metabolic or lymphatic disease that would
             adversely affect the subject's participation in this study or interpretation of
             safety/PK data

         14. HIV, hepatitis B, or hepatitis C positive by serological testing at the screening
             visit

         15. History or presence of malignancy within 5 years prior to screening, except subjects
             who have been treated successfully with no recurrence of basal or squamous cell
             carcinoma of the skin (&lt; 1 year), in situ cervical cancer, or in situ ductal breast
             cancer

         16. Women of reproductive potential who have a positive serum pregnancy test result at the
             screening visit, or a positive urine pregnancy test result at the baseline visit, or
             who do not have their pregnancy test results at the baseline visit

         17. Pregnant or breast-feeding women

         18. Participation in any clinical research study evaluating another investigational drug
             or therapy within 30 days or at least 5 half-lives of the investigational drug,
             whichever is longer, prior to the day 1 visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

